Bayer’s Rally Enters a New Phase as Apollo Cash, German Drug Vote, and a Delayed Court Date Converge

Bayer shares double from August low but face Apollo's €3B injection, German health reform vote, and postponed glyphosate settlement hearing. Overbought RSI signals potential pullback.

Bayer’s stock has nearly doubled from its August 2025 low, but the DAX-listed group now faces a trio of events that will test whether the rally has a durable foundation. This week alone brings a €3 billion equity injection from Apollo Global Management, a Bundestag vote on a health-reform package that Bayer’s own board has denounced, and the postponement of a critical court hearing on a $7.25 billion glyphosate settlement. After a 42.94% surge over the past 30 days and a 32.28% gain since January, the shares are trading at €50.30, down 0.79% from the previous close — a modest pullback that technical indicators suggest may be overdue.

The rally has been driven not by a shift in fundamentals but by a single legal event. The U.S. Supreme Court ruled that federal pesticide-labeling requirements preempt state-law claims, effectively gutting thousands of lawsuits alleging inadequate cancer warnings on glyphosate-based products. The decision transformed Bayer’s risk profile overnight, lifting the stock from a 52-week trough of €25.09 to a high of €53.86 on July 3. Yet the speed of the move has left the shares technically stretched: the Relative Strength Index stands at 71.1, firmly in overbought territory, while annualized 30-day volatility has hit 61.81%. The stock now trades 33.55% above its 200-day moving average of €37.68 and 25.24% above the 50-day line of €40.16 — gaps that historically tend to narrow.

Apollo’s €3 billion capital injection, announced this week, adds a fresh dimension to the narrative. The buyout firm is taking a minority stake in a newly formed subsidiary housing Bayer’s reversible long-acting contraceptive (LARC) business, leaving Bayer with operational control and full consolidation of the unit. The transaction, expected to close in the third quarter of 2026 pending antitrust approval, gives the company breathing room to address looming bond maturities and ongoing litigation costs. For bulls, the deal signals a deliberate balance-sheet repair; for skeptics, it raises questions about why a company with nearly €49 billion in market capitalization needs to sell a stake in one of its pharmaceutical assets.

Today’s Bundestag vote on the Beitragssatzstabilisierungsgesetz — a health-reform bill targeting €18.8 billion in savings by 2027 — represents the most immediate headwind. Bayer’s pharmaceuticals chief, Stefan Oelrich, publicly criticized the package, warning it would undercut profitability at German drug manufacturers. Rivals Eli Lilly and Boehringer Ingelheim have already trimmed their investment commitments, fueling concerns about a broader structural weakening of the sector. The political risk comes at a moment when the stock is already priced for perfection, and any adverse outcome from the vote could trigger profit-taking.

The legal calendar remains the dominant catalyst, but uncertainty has crept in. A Missouri Circuit Court judge on June 30 pushed back the final approval hearing for the multi-billion-dollar class settlement from early July to August 19. The market initially shrugged off the delay — a sign of how much the Supreme Court ruling has reshaped sentiment — but the new date now looms as a pivotal checkpoint. If the court approves the settlement without surprises, the path to fresh highs beyond €53.86 could reopen. Any conditions or additional litigation risk, however, would amplify the volatility that is already running at levels more typical of a speculative mid-cap than a €48.77 billion DAX stalwart.

Technically, the immediate support floor sits at €40.16, the 50-day moving average, while the resistance zone at €53.86 remains the next hurdle. A break below €50 could accelerate selling, but as long as the 200-day line holds, the long-term uptrend is intact. The confluence of Apollo’s balance-sheet lifeline, a contentious German health vote, and a rescheduled court date means the August landscape is anything but quiet. For a stock that has doubled on a single legal ruling, the next few weeks will reveal whether that re-rating can withstand the crosscurrents of politics and high-frequency trading.